Skip to main content

Molecular Templates, Inc.

MTEMDelisted May 22, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001183765

Molecular Templates, Inc. was delisted on May 22, 2025; its insiders filed their last Form 4 on Nov 18, 2024; no institution reported holding it in 13F filings for Q1 2025; no superinvestor held it.

Currency
USD
Source
SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
Updated
Oct 8, 2026, 12:37 PM ET

Income statement

Each column is one fiscal year, newest first.

Income statement of Molecular Templates, Inc., annual
Line itemFY2023FY2022FY2021FY2020FY2019
Period endDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Filing10-K10-K10-K10-K10-K
ReportedMar 29, 2024–Mar 29, 2022Mar 19, 2021Mar 12, 2020
Revenue––––$22.3M
Operating expenses$67.8M$108.6M$118.8M$119.7M$92.7M
Research and development$48.9M$82.4M$84.7M$93.0M$50.5M
Selling, general and administrative$18.9M$26.2M$34.1M$26.7M$20.1M
Operating income-$10.5M-$88.9M-$80.1M-$100.8M-$70.4M
Income tax-$11.0K$53.0K$0$5.00K$0
Net income-$8.12M-$92.7M-$83.0M-$104.9M-$69.4M
EPS, basic$-1.80$-1.65–––
EPS, diluted$-1.80$-1.65–––
Weighted shares, basic4.50M56.3M–––
Weighted shares, diluted4.50M56.3M–––
Margins and growth
Operating margin––––-316.3%
Net margin––––-311.7%
Revenue growth, year over year––––+67.6%

Balance sheet

Each column is one fiscal year, newest first.

Balance sheet of Molecular Templates, Inc., annual
Line itemFY2023FY2022FY2021FY2020FY2019
Period endDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Filing10-K10-K10-K10-K10-K
ReportedMar 29, 2024–Mar 29, 2022Mar 19, 2021Mar 12, 2020
Cash and equivalents$11.5M$32.2M$25.0M$25.2M$85.5M
Short-term investments–$28.9M$118.1M$68.7M$39.6M
Total current assets$16.8M$68.3M$148.2M$101.3M$139.9M
Property, plant and equipment$7.39M$14.6M$19.3M$22.3M$18.2M
Total assets$35.4M$97.5M$192.4M$139.9M$174.2M
Accounts payable$1.52M$504.0K$1.61M$2.35M$1.47M
Total current liabilities$17.3M$57.1M$46.7M$37.6M$35.8M
Long-term debt–$36.2M$35.5M$14.9M$2.94M
Total liabilities$31.2M$112.7M$126.7M$80.5M$71.2M
Shareholders' equity$4.21M-$15.1M$65.7M$59.3M$103.0M

Cash flow statement

Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.

Cash flow statement of Molecular Templates, Inc., annual
Line itemFY2023FY2022FY2021FY2020FY2019
Period endDec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019
Filing10-K10-K10-K10-K10-K
ReportedMar 29, 2024–Mar 29, 2022Mar 19, 2021Mar 12, 2020
Operating cash flow-$41.8M-$89.0M-$30.4M-$83.8M-$25.2M
Capital expenditures$200.0K$3.20M$4.00M$7.39M$9.65M
Free cash flow-$42.0M-$92.2M-$34.4M-$91.2M-$34.9M
Depreciation and amortization$6.64M$7.38M$6.63M$3.92M$1.18M
Stock-based compensation$6.70M$11.9M$16.6M$11.8M$5.86M
Investing cash flow$29.1M$95.3M-$62.4M-$34.7M-$39.7M
Financing cash flow-$9.12M-$265.0K$92.6M$58.9M$65.7M
Net change in cash-$21.8M$6.03M-$235.0K-$59.6M$730.0K
Ratio
Stock-based compensation, % of revenue––––26.3%

Shares outstanding

Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.

Shares outstanding for Molecular Templates, Inc. by cover date
Cover dateShares outstandingChange in a yearFiling
Aug 9, 20246.58M−91.8%SEC
May 6, 20246.58M−88.3%SEC
Apr 22, 20246.58M−88.3%SEC
Mar 25, 20245.37M−90.5%SEC
Nov 6, 20235.37M−90.5%SEC
Aug 7, 202380.6M+43.1%SEC
May 8, 202356.4M0.0%SEC
Apr 24, 202356.4M0.0%SEC

Notes and known gaps

How these numbers are put together, and what they can't tell you.

  • Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
  • Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.

Known gaps

  • Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
  • EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2018, from 13F share counts: 1-for-15 in Q3 2023.
  • For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
  • For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
  • Companies with several share classes, such as Berkshire Hathaway, may have no EPS. Their cover share count adds up the classes but only for the last few filings, so there can be a gap before them.
  • Depreciation and amortization is missing for some companies that report it under their own XBRL tags.